Crizanlizumab-tmca

Class: Blood Formation, Coagulation, and Thrombosis Agents; Miscellaneous
Chemical Name: Immunoglobulin G2, anti-(human P-selectin) (human-Mus musculus monoclonal SelG1 heavy chain), disulfide with human-Mus musculus monoclonal SelG1 light chain, dimer
Molecular Formula: C₆₄₅₈H₉₉₄₈N₁₇₁₂O₂₀₅₀S₅₈
CAS Number: 1690318-25-2
Brands: Adakveo

Medically reviewed by Drugs.com on Nov 22, 2021. Written by ASHP.

Introduction

Crizanlizumab-tmca, a humanized monoclonal antibody, is a selectin blocker.

Uses for Crizanlizumab-tmca

Crizanlizumab-tmca has the following uses:

Crizanlizumab-tmca is a selectin blocker indicated to reduce the frequency of vasoocclusive crises in adults and pediatric patients aged 16 years and older with sickle cell disease.

Crizanlizumab-tmca Dosage and Administration

General

Crizanlizumab-tmca is available in the following dosage form(s) and strength(s):

Injection: 100 mg/10 mL (10 mg/mL) solution in a single-dose vial.

Dosage

It isessentialthat the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:

Pediatric Patients

Dosage and Administration in Adolescents ≥16 Years of Age

Administer crizanlizumab-tmca 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.

If a dose is missed, administer crizanlizumab-tmca as soon as possible.

If crizanlizumab-tmca is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.

If crizanlizumab-tmca is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.

Crizanlizumab-tmca may be given with or without hydroxyurea.

Adults

Dosage and Administration in Adults

Administer crizanlizumab-tmca 5 mg/kg by intravenous infusion over a period of 30 minutes at Week 0, Week 2, and every 4 weeks thereafter.

If a dose is missed, administer crizanlizumab-tmca as soon as possible.

If crizanlizumab-tmca is administered within 2 weeks after the missed dose, continue dosing according to the patient's original schedule.

If crizanlizumab-tmca is administered more than 2 weeks after the missed dose, continue dosing every 4 weeks thereafter.

Crizanlizumab-tmca may be given with or without hydroxyurea.

Cautions for Crizanlizumab-tmca

Contraindications

None.

Warnings/Precautions

Infusion-re...